While it is well accepted that p53 plays a role in apoptosis, less is known as to its involvement in cell differentiation. Here we show that wild-type p53 facilitates IL-6-dependent macrophage differentiation. Treatment of M1/2 cells expressing the temperature-sensitive p53 143 (Val to Ala) mutant, at the wild-type conformation, facilitated the appearance of mature macrophages that exhibited phagocytic activity. Enhancement of differentiation by the p53 143 (Val to Ala) in the wild-type conformation was coupled with the inhibition of apoptosis induction by this protein. In agreement with previous studies, we found that p53 levels were reduced during p53-dependent macrophage differentiation. This occurred when p53 levels before IL-6 stimuli were high. Interestingly, the p53 143 (Val to Ala) protein, at the mutant conformation, enhanced macrophage differentiation, as did the wild-type conformation, whereas the p53 273 (Arg to His) core mutant exerted an inhibitory effect on this pathway. The transcription-deficient p53 molecules, p53 (22-23) and p53 22,23,143, could not induce p53-dependent differentiation. Moreover, the p53 (22-23) protein inhibited the p53-independent differentiation pathway. Interestingly, the p53 (22-23) protein not only blocked IL-6-mediated differentiation, but also induced significant apoptotic cell death, upon IL-6 stimulation. Taken together, our data show that wild-type p53 enhances macrophage differentiation, while various p53 mutant types exert different effects on this differentiation pathway.
Introduction
The differentiation of human hematopoietic cells is a multistep process that is essential for the generation of mature blood cells. 1 Hematopoietic myeloid precursor cells differentiate to form mature granulocytes and macrophages. After exerting their functions, the differentiated cells die via apoptosis. 2 The molecular events that underlie the production of mature myeloid cells and the preceding apoptotic process are not well understood. However, studies of myeloid differentiation suggest that the modulation of this process is mainly at the level of mRNA transcription. 3 The p53 tumor-suppressor gene plays a central role in the regulation of cell fate. p53 is involved in a variety of cell cyclerelated processes including the activation of cell cycle checkpoints, 4 ,5 apoptosis, 6-8 cellular senescence, 9 DNA repair [10] [11] [12] and cell differentiation. 13 The involvement of p53 in cellular differentiation and embryonic development is less characterized than its role in growth arrest and apoptosis. However, p53 has been implicated in the regulation of these processes by studies of both in vitro and in vivo models. Although it was initially reported that p53-null mice develop normally, 14 more detailed analysis pointed to the conclusion that these mice suffer at certain frequencies from developmental abnormalities. 15, 16 In addition to developmental defects, p53 deficiency affects the differentiation of various cell types (reviewed in Almog and Rotter 13 and in Choi and Donehower 17 ). Similarly, introduction or overexpression of p53 in several tumor cell lines induces limited differentiation. Involvement of p53 in differentiation was also demonstrated in hematopoietic cells. It appears that p53 is involved in the differentiation of both the lymphoid and myeloid lineages (reviewed in Almog and Rotter 13 ). Studies in our laboratory have demonstrated a role for p53 in B-cell differentiation. [18] [19] [20] Expression of p53 in HL-60 promyelocytic cell line induced differentiation along the granulocytic 21 or the monocytic pathways. 22, 65 p53 was also implicated in erythroid differentiation. [23] [24] [25] [26] The mechanism that underlies the involvement of p53 in differentiation is poorly understood. Several reports showed that endogenous p53 levels and activities are regulated upon differentiation. p53 expression was shown to increase during the maturation of human hematopoietic cells. 27 On the contrary, a decrease in p53 protein levels was observed upon the differentiation of epidermal keratinocytes, 28 embryonal carcinoma cells 29 and embryonic stem cell lines. 30 Interestingly, the reduction in p53 expression in epidermal keratinocytes 28 and embryonal carcinoma cells 29 was accompanied by an increase in the transcriptional activity of the p53 protein.
It appears that the involvement of p53 in cell differentiation is mediated through its transcriptional activity. The identification of differentiation-induced genes that are transactivated by p53, in reporter assays, further supports this notion.
shown to repress wild-type p53-mediated differentiation in cells expressing both alleles. 20, 25, 31 Several studies have shown that, in cells devoid of wild-type p53, the expression of mutant p53 inhibits differentiation. 19 Moreover, in clinical studies of cancer patients, mutations in p53 frequently correlate with undifferentiated phenotypes of cancers. 35, 36 The M1 murine myeloblastic cell line, which is p53-null, can be induced by interleukin-6 (IL-6) to undergo terminal macrophage differentiation. 37 We found that a derivative of this line, the M1/2 cell line, 38 retains the capacity to differentiate in response to IL-6. We utilized the M1/2 p53-null cell line and M1/2 stable clones expressing various human p53 forms to investigate the role of p53 in IL-6-mediated myeloid differentiation. Using M1/2-derived clones expressing the p53 143 (Val to Ala) temperature-sensitive mutant, we demonstrate that p53 enhances myeloid differentiation. Surprisingly, this effect was observed both at the wild-type and at the mutant conformation. At 321C, the permissive temperature for wild-type p53 expression, IL-6 treatment resulted both in the inhibition of p53-mediated apoptosis and in the facilitation of p53-mediated differentiation. On the contrary, we observed that the p53 273 (Arg to His) bona fide core mutant inhibits myeloid differentiation to some extent. We show that p53-dependent myeloid differentiation requires the transcriptional activity of p53. Moreover, transcriptionally inactive p53, p53 (22) (23) , interferes with p53-independent myeloid differentiation of M1/2 cells and induces apoptosis upon IL-6 treatment. Interestingly, p53-dependent differentiation is accompanied by decrease in p53 protein expression, when the expression before IL-6 stimuli is high. Our results show that, while wild-type p53 facilitates macrophage differentiation, various p53 mutant forms affect this pathway differently.
Results
In this study, we have investigated the involvement of p53 in myeloid differentiation. For that purpose, we utilized the M1/2 p53 nonproducer murine myeloid cell line and M1/2-derived clones expressing various human p53 mutants. 39 First, we examined whether the M1/2 cells retained the ability to differentiate in response to IL-6, as observed with the parental M1 murine myeloblastic cell line. 37 We found that stimulation of M1/2 cells with IL-6 induced the typical blast morphology of macrophage differentiation, as assessed by Giemsa staining (see Figure 2a , vector at 371C). Thus, the M1/2 cell line can serve as a model system for myeloid differentiation.
Effect of IL-6 on p53 143 (Val to Ala) producer, M1/2 cells
To study the effect of wild-type p53 on myeloid differentiation, we utilized M1/2 clones expressing the p53 143 (Val to Ala) protein, which is known as a temperature-sensitive (ts) mutant. 40 Temperature shift of these clones to 321C induces apoptotic cell death, due to wild-type p53 expression. Previously, it was demonstrated that apoptosis induced in M1 cells by the expression of the temperature-sensitive murine mutant p53 135 (Ala to Val) at 321C is blocked by pretreatment with IL-6. 41 We examined whether the p53 143 (Val to Ala) protein expressed in M1/2 cells behaves in a similar manner. For that we analyzed the effect of treatment with IL-6 on the apoptotic percentage of p53 143 (Val to Ala) expressing M1/2 cells, at 321C. Empty vector-expressing cells were included as a control. Apoptosis induction was analyzed by the FACS-based acridine orange (AO) DNA denaturability assay. 42 In agreement with previous studies, we found that in the M1/2 derivative treatment with IL-6 before the shift to 321C significantly reduces the apoptosis percentage of p53 143 (Val to Ala)-expressing cells (Figure 1 ). Thus, IL-6 inhibits the apoptotic process induced by wild-type p53. These results enabled the analysis of wild-type p53 effect on IL-6-induced myeloid differentiation, utilizing the M1/2 clones expressing the temperature-sensitive p53.
It was of interest to examine whether the p53 143 (Val to Ala)-expressing cells underwent cell differentiation, instead of apoptosis. To that end, M1/2 cells expressing the p53 143 (Val to Ala) protein were treated with IL-6, shifted to 321C, the permissive temperature for the wild-type p53 conformation, and 3 days later the differentiation status was examined by Giemsa staining (Figure 2a) . Similar experiments were carried out at 371C, to determine the effect of the p53 143 (Val to Ala) in the mutant conformation on the differentiation process. We found that nontreated M1/2 cells expressing either the empty vector or the p53 143 (Val to Ala) protein exhibited 2-4% differentiated cells. Interestingly, upon IL-6 treatment, both at 321C and at 371C, the p53 143 (Val to Ala)-expressing clone exhibited significantly more differentiating cells than the empty vector control clone. At 321C, 24% of the control cells exhibited macrophage-like morphology, while 49% differentiated cells were found in the p53 143 (Val to Ala)-expressing cells. Likewise, upon IL-6 treatment at 371C, 40% of the control cells underwent differentiation, while in the p53 143 (Val to Ala)-expressing clone the differentiated population reached 90%. Figure 2a Next, it was of interest to determine how functional activities typical to mature macrophages are modulated in the presence and absence of the p53 143 (Val to Ala) protein. The phagocytic activity of the cells, a hallmark of macrophage differentiation, was measured. The ability of the M1/2 cells to phagocytose opsonized Alexa-labeled E. coli bioparticles was employed to measure their phagocytic capacity. In agreement with the Giemsa stains, we observed at 321C that the p53 143 (Val to Ala) in the wild-type conformation dramatically enhanced macrophage differentiation of M1/2 cells (see Figure 2b ). The p53 143 (Val to Ala)-expressing clone exhibited about three-fold of differentiating cells, compared to the empty vector control. Again, at 371C, mutant p53 conformation temperature, the p53 143 (Val to Ala) facilitated the differentiation process significantly. Thus, we concluded that the p53 143 (Val to Ala) protein exerted a promoting effect on myeloid differentiation. This effect was observed both at 321C and at 371C.
Effect of p53 273 (Arg to His) expression on myeloid differentiation
It is worth mentioning that the p53 143 (Val to Ala) temperature-sensitive mutant induces apoptosis, a wild-type p53 feature, at 321C, and is not involved in apoptosis at 371C. The observation that, in the differentiation process, no differences were observed between the two temperatures raises the possibility that temperature-induced conformational changes in p53 are less significant in the latter pathway. Therefore, to assess the effect of mutant p53 on differentiation, we next focused on the bona fide p53 mutant 273 (Arg to His), one of the most frequent mutations in p53 observed in human cancer cells. Cells expressing either the empty vector or the p53 273 (Arg to His) mutant were stimulated with IL-6 for 3 days and subjected to phagocytosis assays. The results are depicted in Figure 3 . We found that the percentage of phagocytosing cells was reduced in the clones expressing p53 273 (Arg to His) protein, compared to the empty vector, p53-null clone. Thus, the p53 273 (Arg to His) mutant inhibited the differentiation to macrophages to some extent. This inhibitory effect of the p53 273 (Arg to His) mutant is in sharp contrast to the facilitation of differentiation by the p53 143 (Val to Ala) mutant. Therefore, it appears that various p53 mutations may influence differently myeloid differentiation.
Effect of transcription-deficient p53 on myeloid differentiation
We next investigated the mechanism that underlines the enhancement of myeloid differentiation by the p53 143 (Val to Ala) protein. To examine the possibility that transcription activation is required for this process, we utilized transcriptiondeficient p53 forms. 39 A double mutation changing Leu to Gln at position 22 and Trp to Ser at position 23 (Gln-22, Ser-23) in the p53 transactivation domain (p53 (22) (23) ) was shown to impair the ability of the wild-type p53 protein to activate transcription. 43 We examined the effect of the transcriptiondeficient double mutant p53 (22) (23) , as well as the p53 22,23,143 triple mutant, on IL-6-induced myeloid differentiation. First, M1/2 clones expressing the p53 (22-23) were subjected to Giemsa staining. Surprisingly, we revealed that the IL6-mediated differentiation observed in the M1/2 control clone is blocked in M1/2 p53 (22-23)-expressing cells (data not shown). To confirm these findings, we performed a phagocytosis assay for the M1/2 p53 (22-23)-expressing cells, after stimulation with IL-6. As seen in Figure 4 , the phagocytic activity in M1/2 cells expressing the p53 (22-23) 39 Induction of differentiation was studied both at 321C and at 371C. As can be seen in Figure 5 , at 321C, wild-type p53 conformation temperature, the enhancement of differentiation by the p53 143 (Val to Ala) was abolished in cells expressing the transcription-defective analog. A similar phenomenon was observed at 371C, the temperature for mutant p53 expression. Based on these observations, the transcriptional activity of p53 is necessary to induce p53-dependent cell differentiation, by the p53 143 (Val to Ala) protein. The requirement for p53-mediated transcription is true for both the wild-type and the mutant conformation. Thus, again no difference was observed between the two temperatures. The transcription-deficient p53 (22-23) behaved like the p53 273 (Arg to His) core mutant in the sense that both exerted a blocking effect on differentiation.
Effect of p53 status on the telomerase activity of IL-6-treated M1/2 clones To further characterize the differentiation status of M1/2 clones, we measured telomerase activity in the cells, which was shown to be repressed during differentiation. 44, 45 The activity of telomerase was detected by the telomeric repeat amplification protocol (TRAP) assay, before and following 3 days of incubation with IL-6 at 371C (Figure 6a ). We found that M1/2 clone containing the p53 143 (Val to Ala) showed enhanced repression of telomerase activity compared to the p53-null control. In contrast, p53 273 (Arg to His)-containing clone did not show any effect. In addition, we found that mutation of the transactivation domain of the p53 143 (Val to Ala) eliminated the enhancement of telomerase repression. These results further confirm our conclusions that p53 143 (Val to Ala) facilitates cell differentiation, while no differentiation is evident with the p53 273 (Arg to His) mutant and with transcription-deficient mutants. To assess in a quantitative manner the kinetics of telomerase activity downregulation, we measured the activity of telomerase using a recently developed real-time TRAP assay. 46 As shown in Figure 6b , there was a gradual and mild inhibition of telomerase activity during the course of the experiment in the p53-null control. In contrast, strong downregulation was observed in p53 143 (Val to Ala) containing cells, starting from day 2 of IL-6 treatment. This lag could be explained by the known long half-life of telomerase.
Next, we performed a kinetic analysis of telomerase activity at 321C. The experiment was done in parallel with the one presented in Figure 6b to enable direct comparison. As could Figure 6c , there was no significant difference between the p53-null control and p53 143 (Val to Ala) expressing cells up to 2 days of IL-6 treatment. However, at day 3, a strong telomerase repression was observed in p53 143 (Val to Ala) containing cells, compared with the p53-null control. These results support our findings of differentiation at 321C, using Giemsa staining and phagocytosis assays.
Effect of p53 status on apoptosis induction in IL-6-treated M1/2 clones Since we observed an inhibitory effect of the p53 (22) (23) protein on IL-6-induced myeloid differentiation, we set experiments to determine the fate of the p53 (22-23) cells following IL-6 treatment. For that purpose, we analyzed apoptosis of p53 (22-23) expressing M1/2 cells, stimulated with IL-6. M1/2 clones expressing the p53 143 (Val to Ala) and the p53-22,23,143 were included as well. Cell cycle and apoptosis induction were mostly analyzed by the FACS-based AO DNA denaturability assay.
42 Figure 7 depicts the apoptotic patterns observed before and following IL-6 treatment. Significant differences in the apoptotic percentage of the various clones were mostly observed three days following IL-6 treatment. Consistent with our previous observations, the M1/ 2 clones investigated, including the p53 (22-23)-expressing clone, exhibit a very low percentage of apoptosis in normal growing conditions. 39 As reported previously for M1 cells, IL-6-mediated differentiation was accompanied by a low incidence of apoptosis in M1/2 cells expressing empty vector. Interestingly, the p53-143-106, which expresses the p53 143 (Val to Ala) protein, underwent less apoptosis than the empty vector. Surprisingly, we observed that IL-6 induced a high percentage of apoptotic cells in M1/2 cells expressing the p53 (22-23) transcription-deficient mutant. In addition, the p53 triple mutant-expressing clone exhibited a higher percentage of apoptotic cells compared to the p53 143 (Val to Ala) clone, but significantly less than the p53 (22) (23) clones. These findings demonstrate that the expression of the transcriptiondeficient p53 in M1/2 cells not only blocks differentiation, but also induces programmed cell death. Previously, we have observed enhancement of chemotherapy-induced apoptosis by the expression of the p53 (22-23) protein. 39 Since IL-6 is a physiological agent, the enhancement of apoptosis in the p53 (22-23)-expressing clone following IL-6 induction, further substantiates our conclusions that p53 may facilitate apoptosis in a manner that does not require p53 to be transcriptionally active.
Effect of IL-6 treatment on p53 protein expression in the M1/2 clones
Several studies have shown that p53 levels are modulated upon differentiation [27] [28] [29] [30] To determine whether p53 protein expression is regulated in our experimental system, we have evaluated p53 protein levels in the M1/2-derived clones, before and after IL-6 treatment. The results are presented in Figure 8 . We first determined the effect of IL-6 stimulation on the expression of the p53 143 (Val to Ala) protein, (clone p53-143-106), in the wild-type conformation. Interestingly, we found that pretreatment with IL-6 reduced the expression of the p53 143 (Val to Ala) protein at 321C (Figure 8a ). We then examined the effect of IL-6 exposure at 371C, on the expression of several p53 mutants. Western blot analysis with the p53 monoclonal antibody pAb1801 (Figure 8b ) revealed that the levels of the p53 (22-23) protein, (clone p53-22, 23-4C), were similar, before and after IL-6 stimulation. Conversely, the p53 143 (Val to Ala) protein levels, (clone p53-143-106), were markedly reduced following IL-6 treatment. This reduction was significantly inhibited in the p53-22, 23, 143-expressing clone, (p53-22, 23, 143-10D), although some reduction was still evident. Moreover, we have observed that the mutant p53 273 (Arg to His) protein levels were slightly reduced following IL-6 induction, but significantly to a lesser extent compared to mutant p53 143 (Val to Ala) protein (data not shown). Taken together, we suggest that a decline in p53 protein levels correlates with involvement of p53 in the myeloid differentiation process. We next investigated the kinetics of the IL-6-mediated reduction in the p53 143 (Val to Ala) mutant at 371C. For that purpose, we used both the p53 monoclonal antibody pAb1801 and the p53 polyclonal antibody. A representative Western blot analysis with the p53 polyclonal antibody is depicted in Figure 8c . We found that, at 48 h following treatment with IL-6, the p53 143 (Val to Ala) protein levels were reduced. These results were confirmed with the pAb1801 monoclonal antibody. Since a decline in p53 protein levels was demonstrated with both antibodies, we conclude that a true decrease in p53 protein expression occurs, rather than conformational changes.
The decline in p53 143 (Val to Ala) protein was observed utilizing the p53-143-106 clone, which expresses high levels of this protein. The same clone was analyzed in the differentiation and apoptosis assays. We then utilized the p53-143-103 clone, which expresses low levels of the p53 143 (Val to Ala) protein. 39 As with p53-143-106, the p53-143-103 clone exhibited enhanced differentiation, compared to the empty vector control, both at 371C and 321C (data not shown). Western blot analysis of p53-143-103 cells following IL-6 stimulation revealed that the p53 143 (Val to Ala) protein levels were similar before and after treatment with IL-6 (Figure 8d ). These findings suggest that the participation of p53 in myeloid differentiation requires low levels of p53.
Discussion
While the involvement of p53 in cell cycle checkpoints and apoptosis is extensively investigated, 4, 5, 47 the role of p53 in cellular differentiation is still poorly characterized. Nevertheless, it was shown in several experimental models that wild-type p53 facilitates cellular differentiation (reviewed in Almog and Rotter 13 ). Indeed, wild-type p53 was found to participate in a variety of differentiation pathways, including muscle cells differentiation, 25 epithelial cell differentiation, 28 ,48-51 B-cell differentiation [18] [19] [20] and erythroid differentiation. [23] [24] [25] [26] Our data support a role for p53 in the myeloid differentiation pathway. We found that the p53 143 (Val to Ala) human temperature-sensitive mutant, at the wild-type conformation, accelerated macrophage differentiation of M1/2 myeloid cells. We observed a differentiation-promoting activity of this protein by analyzing both morphological and functional features of macrophages. These findings are supported by our observations of enhancement of myeloid differentiation in M1/2 clones, which express the murine temperature-sensitive protein, p53 135 (Ala to Val), in the wild-type conformation (data not shown). While previous reports showed the involvement of p53 in myeloid differentiation towards the granulocytic pathway or towards early monocytic differentiation, 21, 22, 65 our results show that p53 regulates late monocytic differentiation as well.
Interestingly, the addition of IL-6 blocked the induction of apoptosis in M1/2 cells expressing p53 143 (Val to Ala) in the wild-type conformation. The results with the M1/2 cells recapitulate similar observations in the parental M1 cell line expressing p53 135 (Ala to Val). 41 However, in the M1 cell line, the presence of p53, did not affect IL-6-mediated differentiation. On the contrary, we demonstrate that in the M1/2 cells the p53 143 (Val to Ala) protein enhances myeloid differentiation. The apparent discrepancies between the results may be explained by the nature of the M1/2 cells. The M1/2 cell line is dependent for its growth on the presence of growth factors, and thus its differentiation status might be more advanced along the myeloid differentiation pathway than that of the M1 cells.
Surprisingly, in our hands, the human temperature-sensitive p53 143 (Val to Ala) protein, at its mutant conformation, exerted differentiation-promoting effects, as did the protein at Figure 8 Modulations in p53 protein levels during myeloid differentiation. Western blot analysis of p53 143 (Val to Ala) protein expression at 321C after IL-6 treatment for 3 days. The nontreated sample at 321C was kept at this temperature for 6 h. The clone used was the p53-143-106. p53 was detected by the p53 monoclonal antibody pAb1801 (a). Western blot analysis of p53 protein expression in M1/2 clones: p53-143-106, p53-22,23-4C and p53-22,23,143-10D, after 3 days stimulation with IL-6 at 371C. p53 was detected by the p53 monoclonal antibody pAb1801 (b). Kinetics of the reduction in the p53 143 (Val to Ala) protein, using the p53-143-106 clone. Cells were harvested at the indicated time points (days), after treatment with IL-6 at 371C, and subjected to Western blot analysis with the p53 polyclonal antibody (c). Quantitation of p53 protein levels in p53-143-103 clone, expressing a low amount of the p53 143 (Val to Ala) protein, after incubation with IL-6 at 371C. Cells were harvested at the indicated time points (days) and the p53 protein was detected using the p53 polyclonal antibody (d)
its wild-type conformation. Likewise, the murine temperaturesensitive mutant, p53 135 (Ala to Val) protein, at the mutant conformation, enhanced the differentiation of M1/2 cells (data not shown). However, the p53 core mutant 273 (Arg to His) inhibited this process. While the p53 143 (Val to Ala) protein is a conformational mutant, the p53 273 (Arg to His) is a DNA contact mutant. Thus, the different impact of these p53 mutants on myeloid differentiation might reflect a difference between the two mutant p53 classes. However, this hypothesis requires further investigation. The notion that mutant p53 might exert a blocking effect on differentiation was demonstrated in several experimental systems, including muscle cells and hematopoietic cells. 20, 25 There are indications that the involvement of p53 in cell differentiation is mediated through its transcriptional activity (reviewed in Almog and Rotter 52 ). For example, transcriptional activation by p53 was shown to be required for the differentiation of K562 human leukemia cells along the erythroid pathway. 25 In agreement, we demonstrate in this study that the involvement of p53 in myeloid differentiation is also mediated by a transcription-dependent mechanism. We found, that while the temperature-sensitive p53 143 (Val to Ala), expressed in the wild-type conformation, enhanced macrophage differentiation of M1/2 cells, a transcriptiondefective p53, p53 (22) (23) , inhibited the differentiation process. Similarly, in M1/2 cells expressing the p53 22, 23, 143 protein in the wild-type conformation, the percentage of differentiating cells was significantly reduced. Thus, the participation of wild-type p53 in myeloid differentiation requires a transcriptionally active p53.
Surprisingly, the transcription-deficient p53 not only lost its capacity to facilitate p53-dependent macrophage differentiation, but also blocked the p53-independent differentiation pathway. These observations suggest that the two pathways are inter-related. Moreover, the interference of the p53 (22) (23) with the induction of p53-independent differentiation represents a 'gain of function' activity of this protein. In addition to preventing terminal myeloid differentiation, the expression of the p53 (22-23) protein induced apoptosis. Previously, we and others have shown that p53-mediated apoptosis may occur through mechanisms that do not involve transactivation by p53. 39, [53] [54] [55] [56] [57] [58] [59] We have demonstrated that the expression of the p53 (22) (23) protein in M1/2 cells enhances chemotherapy-induced apoptosis. 39 The observation that the p53 (22-23) mediates apoptosis upon IL-6 stimulation further substantiates our previous results. Moreover, as IL-6 is a physiological agent, our results support the existence of transcription-independent pathway for p53-mediated apoptosis under physiological conditions.
A blockage in myeloid differentiation and induction of apoptosis were also observed upon deregulated expression of the c-myc oncoprotein. 60 In this case, however, apoptosis was p53-independent. A detailed analysis demonstrated that c-myc induces apoptosis in IL-6-treated myeloid cells through the CD95/Fas pathway. 61 The Fas pathway was also implicated as a mechanism for p53-mediated apoptosis that is transcription-independent. 62 Therefore, it would be interesting to examine whether this mechanism underlies the induction of apoptosis by the p53 (22) (23) protein, upon exposure to IL-6. Several studies have shown that endogenous p53 levels are modulated upon differentiation. [27] [28] [29] [30] In support of these findings, we observed a decrease in p53 levels, if the expression level before IL-6 stimuli was high. The p53 143 (Val to Ala) protein, when expressed at high levels in M1/2 cells, was reduced by IL-6 treatment yet, expression at low levels was unchanged by IL-6 exposure. These observations suggest that p53-dependent differentiation may take place when p53 levels are low. It would be of interest to substantiate this hypothesis by further investigation. Interestingly, although the source of the p53 proteins in our experimental system is exogenous, p53 protein expression was regulated during differentiation. This may imply that the differentiation patterns observed with the various p53 forms represent a physiological pathway.
The involvement of p53 in several pathways, including differentiation and apoptosis, raises the ultimate question as to the factors that determine which pathway will be induced following the activation of p53. Although it is still an unresolved issue, several studies pointed to the possibility that p53 levels are an important determinant in selecting the specific response. Induction of p53 expression in both SaOS 2 and H1299 p53-null cells induced growth arrest at low p53 levels and apoptosis at high levels of p53. 63 Likewise, we observed that the levels of genotoxic stress, which reflect the levels of accumulated p53, determine the onset of p53-dependent DNA repair or p53-dependent apoptosis. 64 In our previous studies, we demonstrated that, while high levels of p53 induce HL-60 cells to undergo apoptosis, low levels of p53 induced, in the same cells, the onset of differentiation. 65 Here we report on a similar correlation between the levels of p53 and the decision towards differentiation or apoptosis of M1/2 cells. The p53 143 (Val to Ala) protein induces apoptosis when expressed at 321C, in the wild-type conformation. However, reduced levels of this protein, by treatment with IL-6, mediate differentiation. It would be interesting to examine whether the reduction in p53 protein expression at 321C is a key event in the blockage of wild-type p53-mediated apoptosis.
In our experimental system, low levels of p53 and p53 transcriptional activation were observed in p53-dependent differentiation. Interestingly, a decrease in p53 protein levels was associated with an increase in transactivation in mouse differentiating keratinocytes 28 and in retinoic acid-induced differentiation of teratocarcinoma cells. 29 In recent years, a major effort in generating new drugs for cancer treatment is aimed at the induction of cell differentiation. Particularly, differentiation induction as a treatment for hematologic malignancies has greatly advanced. 66 IL-6 is one of the cytokines that are currently examined in clinical trials for differentiation therapy. Since we found that different p53 mutants affected differently IL-6-mediated differentiation, it would be interesting to examine the effect of additional p53 mutants on this pathway. Detection of p53 mutants that facilitate IL-6-induced differentiation could offer a powerful approach in the treatment of myeloid cancers, which express these mutants. It should be borne in mind that differentiation induction by the p53 143 (Val to Ala) mutant was coupled with a decrease in its protein levels. Given these observations, it would be important to examine whether other p53 mutant proteins, frequently observed in cancer, are affected similarly p53 and macrophage cell differentiation D Matas et al by IL-6. This would offer a powerful way to modulate the expression of these mutant p53 proteins in cancer cells. Future studies should be aimed at elucidating the molecular mechanisms for these phenomena and examining the clinical implications for cancer therapy.
Materials and Methods

Cell lines and induction of myeloid differentiation
The M1/2 cell line was established in our laboratory from the M1, a p53 nonproducer cell line, by the selection for cells that are dependent on medium enriched with growth factors. 67 Establishment of the M1/2-derived clones expressing various human p53 mutants was described previously. 39 Clones were continuously grown in DMEM containing 10% fetal calf serum and conditioned medium. Each set of experiments was performed with the same batch of conditioned medium. Cells were induced for differentiation with 20 ng/ml human recombinant IL-6 (Calbiochem), after seeding at a concentration of 0.4 Â 10 5 cells/ml.
Giemsa staining
Cells were collected at the indicated times following IL-6 treatment and subjected to cytocentrifugation. The cytospins obtained were fixed with either ethanol or May-Grunwald and then stained with Giemsa to detect morphologic differentiation.
Phagocytosis assays
Phagocytosis assays were conducted using Alexa-conjugated E. coli bioparticles (Molecular probes) and an E. coli opsonising reagent (Molecular probes). Particles were dissolved in PBS containing 0.1% Azid and sonicated to avoid aggregates. Opsonization was carried out for 1 h at 371C. The particles were then washed three times with PBS. Following harvesting and counting of the cells, cells were incubated with the opsonized particles for 2 h at 371C. A similar set of samples was incubated in ice for 2 h, as a control for absorbence. Cells were then washed three times with PBS and analyzed by the FACSort flow cytometer (Beckton-Dickinson), using the CellQuest (Beckton-Dickinson) software. Acquision of the cells was performed after 1 min of incubation with Trypan blue (0.04%, v/v), to quench the signal from particles adsorbed on the cell surface but not yet internalized.
Western blot analysis
Cell extracts for Western blot analysis were lysed in TLB buffer (50 mM Tris pH 7.5; 100 mM NaCl; 1% Triton X-100; 0.5% Na-deoxycholate; 0.1% SDS). The samples were normalized according to quantitation by Bradford assay (Bio-Rad). Then, protein sample buffer (140 mM Tris pH 6.8; 22.4% glycerol; 6% SDS; 10% b-mercaptoethanol and 0.02% bromophenol blue) was added and the samples were boiled for 10 min and loaded on 10% SDS-polyacrylamide gel. The proteins were transferred to nitrocellulose membranes using a semi-dry transfer cell (Bio-Rad). The p53-specific monoclonal antibody PAb-1801 and the p53 polyclonal antibody were used to detect p53. The protein-antibody complexes were detected by using an HRP-conjugated secondary antibody by the super-signal enhanced chemiluminescence system (Pierce). The expression of atubulin was detected by anti-a-tubulin antibody (Sigma), for a quantity control.
FACS analysis of apoptosis
The AO DNA denaturability assay was performed as previously described. 68 Briefly, cells were fixed in 80% ethanol-20% Hanks balanced salt solution (HBSS) and stored at À201C. Cells were washed once with HBSS, resuspended in HBSS containing 0.25 mg/ml RNase and incubated at 371C for 1 h and 15 min.
Cells were then harvested and resuspended in HBSS. Cell suspensions (200 ml) were added to 0.5 ml of 0.1 M HCl for 40 s incubation. Acid denaturation was quenched by the addition of 2 ml of AO (Molecular Probes) staining solution (pH 2.6), containing 90% v/v 0.1 M Na-citrate, 10% v/v 0.2 M Na 2 HPO 4 and 6 mg/ml AO. 42 
Telomerase activity assays
Telomerase activity determinations were performed using a commercial TRAPeze kit (Intergene) according to the manufacturer's nonradioactive protocol, except the cycling conditions were modified as follows: 301C 30 min, 941C 3 min, and 29 cycles of amplification 941C for 30 s, 561C for 30 s, 721C for 30 s. The TRAP reaction was performed using 150 ng lysate.
The real-time quantitative TRAP was performed exactly as described in Wege et al., 46 using 150 ng of lysate. Relative telomerase activity was calculated from the standard curves generated by serial dilutions of the untreated sample.
